Copeptin as a biomarker in heart failure

Area of Science:

• Cardiology
• Biomarkers
• Heart Failure Research

Background:

• Heart failure (HF) is characterized by increased neurohormonal activation.
• Copeptin, a marker for proarginine vasopressin, has established prognostic value across various diseases.
• Elevated copeptin in HF correlates with adverse outcomes, including mortality and hospitalization risk, and HF severity.

Purpose of the Study:

• To evaluate the prognostic value of copeptin in heart failure.
• To compare copeptin with established biomarkers like BNP and NT-proBNP.
• To explore the potential role of copeptin in risk stratification and biomarker-guided therapy for HF.

Main Methods:

• Observational studies analyzing plasma copeptin levels in heart failure patients.
• Comparison of copeptin's prognostic performance against clinical variables and natriuretic peptides (BNP, NT-proBNP).
• Assessment of copeptin in patients hospitalized for HF or myocardial infarction (MI).

Main Results:

• Elevated plasma copeptin in HF is linked to increased mortality and hospitalization risk.
• Copeptin may provide additional prognostic information beyond traditional predictors in HF.
• Copeptin demonstrated superiority over BNP and NT-proBNP in HF patients post-discharge following HF or MI hospitalization.

Conclusions:

• Copeptin is a significant prognostic marker in heart failure.
• It may offer advantages over current biomarkers for predicting adverse outcomes in HF.
• Further randomized trials are essential to clarify copeptin's optimal clinical application in HF management, including risk stratification and targeted therapy.